Responses
Rheumatoid arthritis
Original article
Identification of sarilumab pharmacodynamic and predictive markers in patients with inadequate response to TNF inhibition: a biomarker substudy of the phase 3 TARGET study
Compose a Response to This Article
Other responses
No responses have been published for this article.